Brainsway Ltd BRSYF Stock Profile

Description: Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation. Brainsway Ltd. was founded in 2003 and is based in Jerusalem, Israel.

Keywords: Technology Solutions Alzheimer's Disease Neuroscience Multiple Sclerosis Smoking Psychiatric Diagnosis Schizophrenia Stroke Psychiatry Chronic Pain Smoking Cessation Neurophysiology Neurotechnology Central Nervous System Disease Neuropsychology Sclerosis Treatment Of Depression Autism Bip Bipolar Disorder Brain Disorders Transcranial Magnetic Stimulation Depressive Disorders Pains Obsessive Compulsive Disorders Brainsway Chronic Pains Compulsive Disorders Post Traumatic Stress Disorders Deep Transcranial Magnetic Stimulation Systems Treatment Of Brain Disorders

Home Page: www.brainsway.com

Bynet Building
Jerusalem, 9777518
Israel
Phone: 972 2 582 4030

Officers

Name	Title
Dr. Christopher R. von Jako Ph.D.	Pres & CEO
Mr. Richard Scott Areglado	Sr. VP & CFO
Mr. Hadar Levy	Sr. VP & COO
Mr. Christopher J. Boyer Ph.D.	VP of Global Marketing
Mr. Avner Hagai	Founder & Independent Vice-Chairman
Prof. Abraham Zangen	Co-Founder, Member of Scientific Advisory Board & Director
Dr. Yiftach Roth Ph.D.	Chief Scientist
Mr. Menachem C. Klein Esq.	VP, Gen. Counsel & Corp. Sec.
Dr. Aron Tendler	Chief Medical Officer
Ms. Moria Ankri	VP R&D

Exchange: PINK

Country: US

Currency: US Dollar ($)

Forward PE:	0
Trailing PE:	0
Price-to-Book MRQ:	0.6086
Price-to-Sales TTM:	1.1136
IPO Date:
Fiscal Year End:	December
Full Time Employees:	118

Brainsway Ltd(BRSYF)